CoChat

Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Impaired cardiac microvascular function contributes to cardiovascular complications in diabetes. Glucagon-like peptide-1 (GLP-1) exhibits potential cardioprotective properties in addition to its glucose-lowering effect. This study was designed to evaluate the impact of GLP-1 on cardiac microvascular injury in diabetes and the underlying mechanism involved. Experimental diabetes was induced using streptozotocin in rats. Cohorts of diabetic rats received a 12-week treatment of vildagliptin (dipeptidyl peptidase-4 inhibitor) or exenatide (GLP-1 analog). Experimental diabetes attenuated cardiac function, glucose uptake, and microvascular barrier function, which were significantly improved by vildagliptin or exenatide treatment. Cardiac microvascular endothelial cells (CMECs) were isolated and cultured in normal or high glucose medium with or without GLP-1. GLP-1 decreased high-glucose–induced reactive oxygen species production and apoptotic index, as well as the levels of NADPH oxidase such as p47phox and gp91phox. Furthermore, cAMP/PKA (cAMP-dependent protein kinase activity) was increased and Rho-expression was decreased in high-glucose–induced CMECs after GLP-1 treatment. In conclusion, GLP-1 could protect the cardiac microvessels against oxidative stress, apoptosis, and the resultant microvascular barrier dysfunction in diabetes, which may contribute to the improvement of cardiac function and cardiac glucose metabolism in diabetes. The protective effects of GLP-1 are dependent on downstream inhibition of Rho through a cAMP/PKA-mediated pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db12-1025

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Effects of vildagliptin or exenatide on cardiac function and cardiac glucose metabolism in diabetes. A: Representative mitral flow patterns from pulsed Doppler. B: Quantification of E/A ratio. C: Measurement of left ventricular end-diastolic diameter after 12 weeks of drug treatment. D: Measurement of fractional shortening (FS) after 12 weeks of drug treatment. E: Representative PET/CT scan images from coronal, sagittal, and transverse view from each group. Higher glucose uptake level is shown as an increase in the intensity of red color as indicated on the color scale bar shown. F: Quantification of accumulated 18F-FDG in the heart. Data are expressed as mean ± SD (n = 6). *P <0.05 vs. control group; #P <0.05 vs. Diabetes + vehicle group; &P <0.05 vs. Diabetes + insulin group. DM, diabetes; E, early mitral diastolic wave; A, late mitral diastolic wave; LVEDD, left ventricular end-diastolic diameter.
FIG. 1. Effects of vildagliptin or exenatide on cardiac function and cardiac glucose metabolism in diabetes. A: Representative mitral flow patterns from pulsed Doppler. B: Quantification of E/A ratio. C: Measurement of left ventricular end-diastolic diameter after 12 weeks of drug treatment. D: Measurement of fractional shortening (FS) after 12 weeks of drug treatment. E: Representative PET/CT scan images from coronal, sagittal, and transverse view from each group. Higher glucose uptake level is shown as an increase in the intensity of red color as indicated on the color scale bar shown. F: Quantification of accumulated 18F-FDG in the heart. Data are expressed as mean ± SD (n = 6). *P <0.05 vs. control group; #P <0.05 vs. Diabetes + vehicle group; &P <0.05 vs. Diabetes + insulin group. DM, diabetes; E, early mitral diastolic wave; A, late mitral diastolic wave; LVEDD, left ventricular end-diastolic diameter.CC BY-NC-ND · PubMed Central
FIG. 2. Effects of vildagliptin or exenatide on cardiac microvascular integrity and permeability. A: The surface of cardiac microvessels in control animals was smooth and well-integrated. B: Cardiac microvessels in diabetic animals were visualized to be highly irregular and rough. C: Cardiac microvessels treated with insulin. D and E: Cardiac microvessels with vildagliptin or exenatide treatment exhibited integrity and vessel integration. F: Lanthanum nitrate was regulated to the blood vessel lumen in control animals. G: Lanthanum nitrate was found to diffuse across vessel lumen to the basal lamina in diabetic animals. H: Cardiac microvessels were treated with insulin. I and J: Diffusion of lanthanum nitrate across CMECs was attenuated in vildagliptin or exenatide treatment (scale bar, 2 μm). The extracellular tracer lanthanum nitrate is highlighted with arrows. DM, diabetes.
FIG. 2. Effects of vildagliptin or exenatide on cardiac microvascular integrity and permeability. A: The surface of cardiac microvessels in control animals was smooth and well-integrated. B: Cardiac microvessels in diabetic animals were visualized to be highly irregular and rough. C: Cardiac microvessels treated with insulin. D and E: Cardiac microvessels with vildagliptin or exenatide treatment exhibited integrity and vessel integration. F: Lanthanum nitrate was regulated to the blood vessel lumen in control animals. G: Lanthanum nitrate was found to diffuse across vessel lumen to the basal lamina in diabetic animals. H: Cardiac microvessels were treated with insulin. I and J: Diffusion of lanthanum nitrate across CMECs was attenuated in vildagliptin or exenatide treatment (scale bar, 2 μm). The extracellular tracer lanthanum nitrate is highlighted with arrows. DM, diabetes.CC BY-NC-ND · PubMed Central
FIG. 3. Characterization of CMECs and detection of GLP-1R. A: CMEC monolayer presents cobblestone appearance by phase-contrast microscopy (scale bar, 40 μm). B: Uptake of Dil-acetylated low-density lipoprotein (Dil-Ac-LDL) by immunofluorescence (red, Dil-Ac-LDL; blue, DAPI). C: Expression of GLP-1R by immunofluorescence (green, GLP-1R; scale bar, 10 μm). D: Merge between B and C. E: Western blot analysis for GLP-1R. β-Cells were used as positive control.
FIG. 3. Characterization of CMECs and detection of GLP-1R. A: CMEC monolayer presents cobblestone appearance by phase-contrast microscopy (scale bar, 40 μm). B: Uptake of Dil-acetylated low-density lipoprotein (Dil-Ac-LDL) by immunofluorescence (red, Dil-Ac-LDL; blue, DAPI). C: Expression of GLP-1R by immunofluorescence (green, GLP-1R; scale bar, 10 μm). D: Merge between B and C. E: Western blot analysis for GLP-1R. β-Cells were used as positive control.CC BY-NC-ND · PubMed Central
FIG. 4. Effects of GLP-1 on oxidative stress in high-glucose–induced CMECs. A: GLP-1 inhibits high-glucose–induced superoxide generation in CMECs dose dependently. B: GLP-1 inhibits high-glucose–induced NADPH oxidase activity in CMECs dose dependently. C: Representative images of dihydroethidine (DHE) staining of CMECs (red, DHE; blue, DAPI; scale bar, 25 μm). D: The average fluorescence intensity from five fields was summarized. E–H: Western blot assay for p47phox, gp91phox, p22phox, and p40phox protein expression. *P <0.01 vs. control group; #P <0.05 vs. high-glucose (HG) group; &P <0.01 vs. HG group. Con, control.
FIG. 4. Effects of GLP-1 on oxidative stress in high-glucose–induced CMECs. A: GLP-1 inhibits high-glucose–induced superoxide generation in CMECs dose dependently. B: GLP-1 inhibits high-glucose–induced NADPH oxidase activity in CMECs dose dependently. C: Representative images of dihydroethidine (DHE) staining of CMECs (red, DHE; blue, DAPI; scale bar, 25 μm). D: The average fluorescence intensity from five fields was summarized. E–H: Western blot assay for p47phox, gp91phox, p22phox, and p40phox protein expression. *P <0.01 vs. control group; #P <0.05 vs. high-glucose (HG) group; &P <0.01 vs. HG group. Con, control.CC BY-NC-ND · PubMed Central
FIG. 5. GLP-1 exerted antiapoptotic effect on high-glucose–induced CMECs. A: Representative images of immunostaining for apoptotic (TUNEL) cells. Nuclei were labeled with DAPI (scale bar, 25 μm). B: Quantification of apoptotic nuclei by Image-Pro Plus software. C: Western blot assay for cleaved caspase-3 protein expression. *P <0.05 vs. high-glucose (HG) plus vehicle group; #P <0.05 vs. control plus vehicle group. Con, control.
FIG. 5. GLP-1 exerted antiapoptotic effect on high-glucose–induced CMECs. A: Representative images of immunostaining for apoptotic (TUNEL) cells. Nuclei were labeled with DAPI (scale bar, 25 μm). B: Quantification of apoptotic nuclei by Image-Pro Plus software. C: Western blot assay for cleaved caspase-3 protein expression. *P <0.05 vs. high-glucose (HG) plus vehicle group; #P <0.05 vs. control plus vehicle group. Con, control.CC BY-NC-ND · PubMed Central
FIG. 6. GLP-1 suppressed high-glucose (HG)-induced activation of Rho. A: Western blot assay for Rho protein expression. B: Western blot assay for ROCK protein expression. *P <0.05 vs. control group; #P <0.05 vs. HG group; &P <0.05 vs. HG plus GLP-1 group. Con, control; H89, PKA inhibitor.
FIG. 6. GLP-1 suppressed high-glucose (HG)-induced activation of Rho. A: Western blot assay for Rho protein expression. B: Western blot assay for ROCK protein expression. *P <0.05 vs. control group; #P <0.05 vs. HG group; &P <0.05 vs. HG plus GLP-1 group. Con, control; H89, PKA inhibitor.CC BY-NC-ND · PubMed Central
FIG. 7. Effects of GLP-1, fasudil, and H89 on high-glucose (HG)-induced oxidative stress in CMECs. A: Representative diagram showing dihydroethidine (DHE) staining of CMECs (red, DHE; blue, DAPI; scale bar, 25 μm). B: The average fluorescence intensity from five fields was summarized. C: Superoxide generation of CMECs in different groups. D: Western blot assay for p47phox protein and gp91phox protein expression. E and F: Quantitative analysis of p47phox and gp91phox expression. *P <0.01 vs. control group; #P <0.01 vs. HG group; &P <0.05 vs. HG plus GLP-1 group. Con, control; H89, PKA inhibitor.
FIG. 7. Effects of GLP-1, fasudil, and H89 on high-glucose (HG)-induced oxidative stress in CMECs. A: Representative diagram showing dihydroethidine (DHE) staining of CMECs (red, DHE; blue, DAPI; scale bar, 25 μm). B: The average fluorescence intensity from five fields was summarized. C: Superoxide generation of CMECs in different groups. D: Western blot assay for p47phox protein and gp91phox protein expression. E and F: Quantitative analysis of p47phox and gp91phox expression. *P <0.01 vs. control group; #P <0.01 vs. HG group; &P <0.05 vs. HG plus GLP-1 group. Con, control; H89, PKA inhibitor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 181

Metadata

Authors
Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., Wang, H., Ren, J., & Cao, F.
Affiliations
  • Xijing Hospital (CN)
  • University of Wyoming (US)
Corresponding author
Cao, Feng
Venue
Diabetes
Published
2013-04-16
Volume
62
Issue
5
Pages
1697-1708
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2117213923
Cited by
179
References
54
Citations by year
2026: 7 · 2025: 8 · 2024: 12 · 2023: 6 · 2022: 13 · 2021: 11 · 2020: 11 · 2019: 15 · 2018: 9 · 2017: 21 · 2016: 16 · 2015: 21 · 2014: 22 · 2013: 7
FWCI
17.31
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Keywords
glucagon-like peptide-1, vildagliptin, exenatide, DPP-4 inhibitors, cardiac microvascular endothelial cells, cAMP/PKA signaling, Rho, oxidative stress, apoptosis, NADPH oxidase, cardiac glucose metabolism, streptozotocin-induced diabetes
MeSH terms
Exenatide, Cyclic AMP, Animals, Cardiotonic Agents, Cells, Cultured, Diabetic Angiopathies, Disease Models, Animal, Endothelium, Vascular, Heart Ventricles, Hyperglycemia, Hypoglycemic Agents, Male, Peptides, Random Allocation, Venoms, Second Messenger Systems, Rats, Sprague-Dawley, Oxidative Stress, rho GTP-Binding Proteins, Rats, Glucagon-Like Peptide 1, AMP-Activated Protein Kinases, Microvessels, Diabetic Cardiomyopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.